Interaction between paliperidone and carbamazepine

Therapeutic Drug Monitoring

Volumn 35, Issue 5, 2013, Pages 649-652

  Yasui Furukori, Norio ^a   Kubo, Kazutoshi ^a   Ishioka, Masamichi ^a   Tsuchimine, Shoko ^a   Inoue, Yoshimasa ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

carbamazepine; interaction; P glycoprotein; paliperidone

Indexed keywords

BIPERIDEN; CARBAMAZEPINE; FLUNITRAZEPAM; PALIPERIDONE; SENNOSIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; DISEASE EXACERBATION; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; EVENING DOSAGE; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MORNING DOSAGE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCHIZOPHRENIA; TANDEM MASS SPECTROMETRY;

ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; CARBAMAZEPINE; DRUG INTERACTIONS; HUMANS; ISOXAZOLES; PYRIMIDINES; SCHIZOPHRENIA;

EID: 84885021774     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3182966c2f     Document Type: Article

References (31)

1. Yang LP, Plosker GL. Paliperidone extended release. CNS Drugs. 2007; 21:417-427
2. Schotte A, Janssen PF, Gommeren W, et al. Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology (Berl). 1996;124:57-73
3. Vermeir M, Naessens I, Remmerie B, et al. Absorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humans. Drug Metab Dispos. 2008;36:769-779
4. Cleton A, Talluri K, Leempoels J, et al. No pharmacokinetic interaction between trimethorpim and paliperidone in healthy subjects (Abstract). Clin Pharmacol Ther. 2006;79:22
5. Wang JS, Ruan Y, Taylor RM, et al. The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein. Int J Neuropsychopharmacol. 2004;7:415-419
6. Doran A, Obach RS, Smith BJ, et al. The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: Evaluation using the MDR1A/1B knockout mouse model. Drug Metab Dispos. 2005;33:165-174
7. Otani K, Yasui N, Kaneko S, et al. Carbamazepine augmentation therapy in three patients with trazodone-resistant unipolar depression. Int Clin Psychopharmacol. 1996;11:55-57
8. Otani K, Ishida M, Yasui N, et al. Interaction between carbamazepine and bromperidol. Eur J Clin Pharmacol. 1997;52:219-222
9. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine 10,11-epoxide. Clin Pharmacokinet. 1986;11:177-198
10. Wietholtz H, Zysset T, Kreiten K, et al. Effect of phenytoin, carbamazepine, and valproic acid on caffeine metabolism. Eur J Clin Pharmacol. 1989;36:401-406
11. Pirmohamed M, Allott R, Green VJ, et al. Lymphocyte microsomal epoxide hydrolase in patients on carbamazepine therapy. Br J Clin Pharmacol. 1994;37:577-581
12. Yue QY, Tomson T, Säwe J. Carbamazepine and cigarette smoking induce differentially the metabolism of codeine in man. Pharmacogenetics. 1994;4:193-198
13. Bertilsson L, Tybring G, Widen J, et al. Carbamazepine treatment induces the CYP3A4 catalysed sulphoxidation of omeprazole, but has no or less effect on hydroxylation via CYP2C19. Br J Clin Pharmacol. 1997; 44:186-189
14. Oscarson M, Zanger UM, Rifki OF, et al. Transcriptional profiling of genes induced in the livers of patients treated with carbamazepine. Clin Pharmacol Ther. 2006;80:440-456
15. Spina E, Avenoso A, Facciolà G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone: Effect of comedication with carbamazepine or valproate. Ther Drug Monit. 2000;22:481-485
16. Spina E, Scordo MG, Avenso A. Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity. J Clin Psychopharmacol. 2001;21:108-109
17. Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: Its relationship with CYP2D6 genotypes. Psychopharmacology (Berl). 2002;162:50-54
18. Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther. 1993;54:257-268
19. Yasui-Furukori N, Saito M, Nakagami T, et al. Clinical response to risperidone in relation to plasma drug concentrations in acutely exacerbated schizophrenic patients. J Psychopharmacol. 2010;24:987-994
20. Yasui-Furukori N, Mihara K, Takahata T, et al. Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: Lack of impact of MDR-1 genotypes. Br J Clin Pharmacol. 2004;57: 569-575
21. Yasui-Furukori N, Tsuchimine S, Saito M, et al. Comparing the influence of dopamine D2 polymorphisms and plasma drug concentrations on the clinical response to risperidone. J Clin Psychopharmacol. 2011;31:633-637
22. Lu Y, Yan Y, Wang XF. Antiepileptic drug-induced multidrug resistance P-glycoprotein overexpression in astrocytes cultured from rat brains. Chin Med J (Engl). 2004;117:1682-1686
23. Giessmann T, May K, Modess C, et al. Carbamazepine regulates intestinal P-glycoprotein and multidrug resistance protein MRP2 and influences disposition of talinolol in humans. Clin Pharmacol Ther. 2004;76:192-200
24. Owen A, Goldring C, Morgan P, et al. Induction of P-glycoprotein in lymphocytes by carbamazepine and rifampicin: The role of nuclear hormone response elements. Br J Clin Pharmacol. 2006;62:237-242
25. Yang HW, Liu HY, Liu X, et al. Increased P-glycoprotein function and level after long-Term exposure of four antiepileptic drugs to rat brain microvascular endothelial cells in vitro. Neurosci Lett. 2008;434:299-303
26. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem. 2001; 276:14581-14587
27. Yamada S, Yasui-Furukori N, Akamine Y, et al. Effects of the P-glycoprotein inducer carbamazepine on fexofenadine pharmacokinetics. Ther Drug Monit. 2009;31:764-768
28. Yasui-Furukori N, Kondo T, Mihara K, et al. Significant dose effect of carbamazepine on reduction of steady-state plasma concentration of haloperidol in schizophrenic patients. J Clin Psychopharmacol. 2003;23: 435-440
29. Arana GW, Goff DC, Friedman H, et al. Does carbamazepine-induced reduction of plasma haloperidol levels worsen psychotic symptoms? Am J Psychiatry. 1986;143:650-651
30. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry. 2011;44:195-235
31. Kirschbaum KM, Henken S, Hiemke C, et al. Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. Behav Brain Res. 2008;188:298-303